Human Fibroblast Interferon for Clinical Trials: Production, Partial Purification, and Characterization
Alfons Billiau(Rega Institute for Medical Research), Piet De Somer(Rega Institute for Medical Research), Fred Van Leuven(KU Leuven), Jean‐Jacques Cassiman(KU Leuven), Herman Van den Berghe(Brigham and Women's Hospital), V. G. Edy, Marc De Ley(Rega Institute for Medical Research), Jo Van Damme(Cliniques Universitaires Saint-Luc)
Cited by 48
Related Papers
Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain
|Journal of Biological Chemistry|1999|668
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model
|Journal of Clinical Investigation|2004|622
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency
|Proceedings of the National Academy of Sciences|1999|523
Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/β-TrCP Axis
|Molecular and Cellular Biology|2012|473